Akeso vs Merck: China’s Lung Cancer Showdown Nobody Asked For
Akeso, the Chinese biotech underdog, decided to keyboard-warrior challenge Merck’s cancer titan Keytruda with its own lung cancer drug—because what the world needed was another medical cage match. They boldly claimed increased patient survival, which is nice, but how much longer can we use ‘survival’ as a marketing pitch without sounding like a reality TV show eviction notice? Details like trial timelines, money spent, and precise survival rates were mercifully absent—maybe next press release. Meanwhile, in some lab somewhere, a scientist is probably wondering why their name isn’t in this brief yet operatic drama.
Share the Story
(1 of 3)Nothing says biotech bragging rights like promising to out-survive Merck's star drug while leaving everyone guessing the fine print. The lung cancer weapon race now has a new player, and surprisingly, no one flinched. Medical turf wars: battle royale edition.
China’s Akeso crashing Merck’s cancer party with some vague survival talk. Watch as pharmaceutical diplomacy turns into a gladiator match, minus the lions but double the patent battles.
Akeso just whispered ’survival’ louder than Merck’s Keytruda, proving in biotech PR that shouting hopeful words sometimes counts more than numbers. Meanwhile, patients wait for footnotes.
Source: Statnews | Published: 8/26/2025 | Author: Jonathan Wosen
More Articles in Health
VP Vance Heads to Pakistan to Broker Peace, Backed by Kushner and Trump’s Threats
Augusta Airport Now Essentially a Billionaires' Landing Strip, Not a Regional Hub
FAA Turns to Gamers Because Real Air Traffic Controllers Keep Vanishing
Telehealth Startup Outsources Doctors to AI and Angolan Phone Lines
Widow Turns Frozen Sperm Time Capsule Into Baby After 10-Year Hiatus
OpenAI CEO Temporarily Downgrades from AI Overlord to Human POTS Patient
Woman Quits Job at 38 to Audit Diaper Changing as Full-Time Gig
Utah Lets Robot Shrink Prescribe Meds, Because What Could Go Wrong?
